Source comparison
CJC-1295 No DAC Stacking: Comparison of Research-Grade Peptide Sources
Research peptide quality varies significantly by supplier, with purity, sequence accuracy, and sterility representing the three critical quality determinants. CJC-1295 no DAC and GHRP bioactivity depends on exact amino acid sequencing. A single substitution or
This comparison does not assign a generated winner or score.
- Research peptide quality varies significantly by supplier, with purity, sequence accuracy, and sterility representing the three critical quality determinants. CJC-1295 no DAC and GHRP bioactivity depends on exact amino acid sequencing. A single substitution or deletion renders the compound inactive or produces off-target receptor binding. The table below compares quality markers and verification standards across peptide sourcing categories.
- Research-grade supplier (503B-registered)
- HPLC + mass spectrometry for every batch; ≥98% purity documented
- Full amino acid sequencing via LC-MS; sequence fidelity confirmed
- Endotoxin testing (LAL assay); sterility per USP <71>
- Lyophilized stability data provided; 24-month at −20°C verified
- $65–95 for CJC-1295 no DAC; $55–85 for GHRPs
- Highest reproducibility and regulatory traceability; suitable for peer-reviewed research requiring documented peptide characterization
- Generic research supplier (non-503B)
- Certificate of analysis provided but not batch-specific; claimed purity 95–98%
- Sequence claimed but not independently verified for every batch
- Sterility claimed; no endotoxin data
- Stability data generic or absent
- $35–60 for CJC-1295 no DAC; $30–55 for GHRPs
- Variable quality; acceptable for preliminary feasibility studies but inadequate for publication-grade research where peptide characterization must be documented
- Overseas direct import
- No independent verification; purity claimed by manufacturer only
- Sequence not verifiable; occasional reports of wrong peptide supplied
- No sterility or endotoxin testing
- No stability data
- $15–40 for CJC-1295 no DAC; $12–35 for GHRPs
- High failure risk; cost savings negated by experiment failures due to inactive or contaminated product; unsuitable for any formal research application
- The cost differential reflects verification infrastructure, not peptide synthesis cost. Research-grade suppliers like Real Peptides maintain in-house HPLC and mass spectrometry equipment to verify every batch before release. This prevents sequence errors, contamination, and mislabeling that generic suppliers occasionally pass through. Studies attempting to reproduce published results with unverified peptides frequently fail not because the protocol was wrong, but because the peptide contained 85% purity (15% related peptide fragments) or incorrect sequence length. The National Institutes of Health now recommends source documentation for all peptides used in federally funded research, specifically requiring batch-specific purity and sequence verification. A standard that eliminates most non-503B suppliers from eligibility.